Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also…
| Price | $7.73 |
|---|---|
| Market cap | $504.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NYSE |
| 52-week range | 5.37-17.58 |
| Beta | 1.77 |
Explore DNA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.